Sumaxin Wash

SUMAXIN WASH- sulfacetamide sodium and sulfur solution
Medimetriks Pharmaceutical inc

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

DESCRIPTION: Sodium sulfacetamide is a sulfacetamide with antibacterial activity while sulfur acts as a keratolytic agent. Chemically sodium sulfacetamide is N-[(4-aminophenyl) sulfonyl]-acetamide, monosodium salt, monohydrate. Each mL of Sumaxin (sodium sulfacetamide 9% and sulfur 4%) Wash contains 90mg of sodium sulfacetamide and 40 mg of sulfur in a formulation consisting of: aloe, butylated hydroxytoluene, cetyl alcohol, disodium oleamido MEA sulfosuccinate, edetate disodium, fragrance, glyceryl stearate/PEG-100 stearate, green tea, magnesium aluminum silicate, methylparaben, propylparaben, purified water, sodium cocoyl isethionate, sodium methyl cocoyl taurate, sodium thiosulfate, stearyl alcohol, xanthan gum.

CLINICAL PHARMACOLOGY: The most widely accepted mechanism of action of sulfacetamides is the Woods-Fildes theory, which is based on the fact the sulfacetamides act as competitive antagonists to para-aminobenzoic acid (PABA), an essential component for bacterial growth. While absorption through intact skin has not been determined, sodium sulfacetamide is readily absorbed from the gastrointestinal tract when taken orally and excreted in the urine, largely uncharged. The biologial half-life has variously been reported as 7 to 12.8 hours. The exact mode of action of sulfur in the treatment of acne is unknown, but it has been reported that it inhibits the growth of Propionibacterium acnes and the formation of free fatty acids.

INDICATIONS: Sumaxin (sodium sulfacetamide 9% and sulfur 4%) Wash is indicated for the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.

CONTRAINDICATIONS: Sumaxin (sodium sulfacetamide 9% and sulfur 4%) Wash are contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. Sumaxin (sodium sulfacetamide 9% and sulfur 4%) Wash is not to be used by patients with kidney disease.

WARNINGS: Although rare, sensitivity to sodium sulfacetamide may occur. Therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. Systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice, and contact dermatitis indicate hypersensitivity to sulfonamides. Particular caution should be employed if areas of denuded or abraded skin are involved.

FOR EXTERNAL USE ONLY: Keep away from eyes. Keep out of reach of children. Keep container tightly closed.

PRECAUTIONS: General — If irritation develops, use of the product should be discontinued and approriate therapy instituted. Patients should be carefully observed for possible local irritation or sensitization during long-term therapy. The object of this therapy is to achieve desquamation without irritation, but sodium sulfacetamide and sulfur can cause reddening and scaling of the epidermis. These side effects are not unusual in the treatment of acne vulgaris, but patients should be cautioned about the possibility.

Information for patients — Avoid contact with eyes, eyelids, lips and mucous membranes. If accidental contact occurs, rinse with water. If excessive irritation develops, discontinue use and consult your physician.

PREGNANCY: Category C — Animal reproduction studies have not been conducted with Sumaxin (sodium sulfacetamide 9% and sulfur 4%) Wash . It is also not know whether Sumaxin (sodium sulfacetamide 9% and sulfur 4%) Wash can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sumaxin (sodium sulfacetamide 9% and sulfur 4%) Wash should be given to a pregnant woman only if clearly needed.

NURSING MOTHERS: It is not known whether sodium sulfacetamide is excreted in the human milk following topical use of Sumaxin (sodium sulfacetamide 9% and sulfur 4%) Wash. However, small amounts of orally administered sulfonamides have been reported to be eliminated in human milk. In view of this and because many drugs are excreted in human milk, caution should be exercised when Sumaxin (sodium sulfacetamide 9% and sulfur 4%) Wash is administered to a nursing woman.

PERIATRIC USE: Safety and effectiveness in children under the age of 12 have not been established.

ADVERSE REACTIONS: Although rare, sodium sulfacetamide may cause local irritation.

DOSAGE AND ADMINISTRATION: Apply Sumaxin (sodium sulfacetamide 9% and sulfur 4%) Wash once or twice daily to affected areas, or as directed by your physician. Wet skin and liberally apply to areas to be cleansed. Massage gently into skin for 10-20 seconds,, working into a full lather, rinse thoroughly and pat dry. If drying occurs, it may be controlled by rinsing off Sumaxin (sodium sulfacetamide 9% and sulfur 4%) Wash sooner or using less often.

HOW SUPPLIED: Sumaxin (sodium sulfacetamide 9% and sulfur 4%) Wash is availible in 16oz. bottle, NDC 43538-130-16.

Store at controlled room temperature 15°-30°C (59°-86°F). Protect from freezing.


image of carton
(click image for full-size original)

image of label
(click image for full-size original)

image of sample label
(click image for full-size original)

image of cartonimage of labelimage of sample label
sodium sulfacetamide 9%-sulfur 4% solution
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:43538-130
Route of Administration TOPICAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Sulfacetamide Sodium (Sulfacetamide) Sulfacetamide Sodium 90 mg in 1 g
Sulfur (Sulfur) Sulfur 40 mg in 1 g
Inactive Ingredients
Ingredient Name Strength
Butylated hydroxytoluene
Cetyl alcohol
edetate disodium
magnesium aluminum silicate
sodium thiosulfate
stearyl alcohol
xanthan gum
# Item Code Package Description Multilevel Packaging
1 NDC:43538-130-16 1 BOTTLE (BOTTLE) in 1 CARTON contains a BOTTLE
1 453.5 g in 1 BOTTLE This package is contained within the CARTON (43538-130-16)
2 NDC:43538-130-99 12 g in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
unapproved other 10/30/2009
Labeler — Medimetriks Pharmaceutical inc (019903816)
Registrant — Groupe Parima inc (252437850)
Name Address ID/FEI Operations
Groupe Parima inc 252437850 manufacture

Revised: 10/2009 Medimetriks Pharmaceutical inc

All resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2020. All Rights Reserved.